Clinical trial
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell…
NCT00093756 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00093756 |
|---|---|
| Title | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer |
| Official title | Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | 3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin |
| Enrollment | 52 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2012 |
| Completion | May 1, 2013 |
| First posted | Oct 8, 2004 |
| Last update posted | Dec 7, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: